These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 29474302)

  • 21. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
    Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
    Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
    Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
    Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Bressler SB; Melia M; Glassman AR; Almukhtar T; Jampol LM; Shami M; Berger BB; Bressler NM;
    Retina; 2015 Dec; 35(12):2516-28. PubMed ID: 26035510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRAGMATISM OF RANDOMIZED CLINICAL TRIALS ON RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA: Impact on Clinical Outcomes.
    Stewart S; Yeong JL; Virgili G; Azuara-Blanco A; Lois N
    Retina; 2020 May; 40(5):919-927. PubMed ID: 30789463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema.
    Ebneter A; Waldmeier D; Zysset-Burri DC; Wolf S; Zinkernagel MS
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):549-555. PubMed ID: 27714513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.
    Karst SG; Lammer J; Mitsch C; Schober M; Mehta J; Scholda C; Kundi M; Kriechbaum K; Schmidt-Erfurth U
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):49-58. PubMed ID: 29080915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-life experience of ranibizumab for diabetic macular edema in Taiwan.
    Tsai MJ; Hsieh YT; Peng YJ
    Int Ophthalmol; 2019 Jul; 39(7):1511-1522. PubMed ID: 29926364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ASSOCIATION OF SERUM VASOGENIC AND PROINFLAMMATORY FACTORS WITH CLINICAL RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR DIABETIC MACULAR EDEMA.
    Brito PS; Costa JV; Barbosa-Matos C; Costa SM; Correia-Pinto J; Silva RM
    Retina; 2021 Feb; 41(2):345-354. PubMed ID: 32453069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four-year real-world study.
    Granstam E; Rosenblad A; Modher Raghib A; Granström T; Eriksson JW; Lindholm Olinder A; Leksell J
    Acta Ophthalmol; 2020 Jun; 98(4):360-367. PubMed ID: 31656056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANALYSIS OF RETINAL DEGENERATIVE CHANGES IN DIABETIC MACULAR EDEMA AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Boiko EV; Maltsev DS
    Retina; 2018 Jul; 38(7):1324-1330. PubMed ID: 28492427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COMBINED INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA: Two-Year Randomized Single-Blind Controlled Trial Results.
    Lafuente M; Ortín L; Argente M; Guindo JL; López-Bernal MD; López-Román FJ; García MJ; Domingo JC; Lajara J
    Retina; 2017 Jul; 37(7):1277-1286. PubMed ID: 27787443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
    Ehlers JP; Uchida A; Hu M; Figueiredo N; Kaiser PK; Heier JS; Brown DM; Boyer DS; Do DV; Gibson A; Saroj N; Srivastava SK
    Ophthalmol Retina; 2019 Dec; 3(12):1056-1066. PubMed ID: 31473172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 μg/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I).
    Singer MA; Miller DM; Gross JG; Greven CM; Kapik B; Bailey C; Ghanchi F; Kuppermann BD
    Ophthalmic Surg Lasers Imaging Retina; 2018 Sep; 49(9):698-706. PubMed ID: 30222805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema.
    Bressler SB; Glassman AR; Almukhtar T; Bressler NM; Ferris FL; Googe JM; Gupta SK; Jampol LM; Melia M; Wells JA;
    Am J Ophthalmol; 2016 Apr; 164():57-68. PubMed ID: 26802783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema.
    Felfeli T; Juncal VR; Hillier RJ; Mak MYK; Wong DT; Berger AR; Kohly RP; Kertes PJ; Eng KT; Boyd SR; Altomare F; Giavedoni LR; Muni RH
    Am J Ophthalmol; 2019 Oct; 206():176-183. PubMed ID: 30959004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
    Bahrami B; Hong T; Schlub TE; Chang AA
    Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study.
    Farinha C; Martins A; Neves A; Soares R; Ruão M; Ornelas M; Neves P; Gomes Rodrigues F; Coelho C; Silva R
    Ophthalmologica; 2019; 241(1):1-8. PubMed ID: 29886497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema.
    Morioka M; Takamura Y; Yamada Y; Matsumura T; Gozawa M; Inatani M
    Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2301-2307. PubMed ID: 30238189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.